Living our strategy

Our current strategy is to develop innovative therapies for the treatment of cancer and other significant diseases using our unique mAb platform. Cancer is our focus while other diseases are currently pursued through partnerships. During 2017, we reached several milestones in our strategy. The strategic focus areas, our key achievements in 2017 as well as anticipated milestones in 2018 and aspirations beyond 2018 are outlined here.

Focus area	Key achievements in 2017	Anticipated milestones in 2018	Aspirations beyond 2018
Advance our proprietary clinical pipeline of mAb mixture product candidates towards regulatory approval and commercial launch. Our mAb mixture platform, knowledge of cancer biology, as well as our clinical, regulatory, and manufacturing expertise, provide us with the ability to develop and advance oncology products through to commercialization.	• Sym004 – Reporting of compelling data from a randomized Phase 2b trial, which enrolled 254 patients with late-stage mCRC who had become refractory to prior EGFR antibody therapies. • Sym004 – Advancement of Phase 2a trial in glioblastoma patients. • Sym013 – Advancement of Phase 1 trial in patients with advanced epithelial tumors. • Sym015 – Advancement of Phase 1b/2a trial in patients with advanced solid tumors.	• Sym004 – Further advancement of Sym004 in biomarker-selected mCRC patients. • Sym004 – Continue Phase 2a trial in glioblastoma patients. • Sym013 – Complete Phase 1 trial and initiate Phase 2a trials in epithelial tumors. • Sym015 – Continue Phase 1b/2a trial in patients with advanced solid tumors.	• Multiple drugs in late-stage development for multiple indications. • Sym004 – Complete additional trials in biomarker selected mCRC patients. • Sym004 – Complete Phase 2a glioblastoma trial and evaluate expansion opportunities. • Sym013 – Complete Phase 2a trial in epithelial tumors. • Sym015 – Complete Phase 1b/2a trial in patients with MET amplified solid tumors.
Develop precision medicine products by focusing on biomarker-defined patient populations with significant unmet medical needs, including where expedited regulatory pathways may be available. Since significant diversity exists in each individual cancer patient's prognosis and response to treatment is due in part to molecular heterogeneity, identification of biomarkers can help predict clinical outcome and inform treatment selection.	• Sym004 – Data from Phase 2b trial in late-stage mCRC patients identified as "Triple Negative mCRC" population, who obtained a clinically meaningful median overall survival improvement. • Sym013 – progressing toward identification of Phase 2a dose and further advancement of biomarker program.	• Sym004 – Continue to evaluate other indications where Sym004 might confer a therapeutic benefit in biomarker-defined patient populations. • Sym013 – Continue identification of relevant biomarkers for Phase 2a trials in epithelial tumors. • Identify other biomarker-defined populations that may benefit from our mAb mixture approach.	• Deploy precision-medicine approaches eligible for breakthrough therapy designation and/or expedited regulatory approval.

Our strategy builds on a number of key strengths

- Phase 2b data support the hypothesis for Sym004 as a new significant therapeutic option as precision medicine for late-stage metastatic colorectal cancer.
- We maintain a broad and differentiated clinical pipeline of multiple product candidates, each for multiple indications.
- Our antibody mixture platform, together with our regulatory knowledge and manufacturing capabilities, provide us with a fully integrated approach to the development of cancer therapies.
- Our proprietary pipeline has broad intellectual property protection.
- Our mAb technology platform is validated through partnerships with global biopharmaceutical companies.
- Our experienced leadership team has in-depth industry knowledge and a track record of successful drug development.

Focus area	Key achievements in 2017	Anticipated milestones in 2018	Aspirations beyond 2018
Continue to leverage and invest in our mAb mixture platform to discover and develop additional product candidates, including in the fields of immuno-oncology and other disease areas. We intend to use our antibody discovery technology platform to continue to identify new mAbs and mAb mixtures that may offer a therapeutic benefit.	• Initiation of Phase 1 trial with Sym021, an anti-programmed cell death protein 1 (PD-1) mAb, under our Shire immune-oncology program. • Initiation by Genentech of a Phase 1b trial initiated with Sym009 conjugated to an antibiotic agent targeting staphylococcus aureus bacteremia.	• Additional immuno-oncology targets in Phase 1a trials. • Discovery of new targets and advancement of known targets to pre-clinical phase.	• Clinical development of Immuno-oncology products. • Validate platform in other disease areas than oncology and infectious diseases.
Continue to selectively pursue collaborations and other partnering opportunities with leading bio-pharmaceutical companies. We may consider collaborations with additional strategic partners both within and outside the field of oncology. Our ability to build collaborations is exemplified by our collaborations with Shire (immuno-oncology) and Genentech (infectious diseases).	• Validation of existing collaborations with Shire and Genentech through entry of programs into the clinic providing further substantiation of the efficiency of Symphogen's platform approach.	• Continuing to seek value-generating partnerships, including with large biotechnology and pharmaceutical companies with late-stage development and commercialization capabilities, to leverage our internal capabilities.	• Engagement in significant partnerships with clinical development and commercialization partners inside and outside the field of oncology.